---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-26-000098"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2026-08-04T20:05:45+00:00"
generated_at: "2026-08-04T20:07:41.723464+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spyre reports Q2 net loss $36.2M; cash $1.15B; positive Phase 2 data for SPY001/SPY002 in UC

## Summary
- Net loss of $36.2M in Q2 2026 vs $36.7M in Q2 2025; R&D expenses rose to $65.5M from $40.1M.
- Cash, equivalents, and marketable securities of $1,145.3M as of June 30, 2026; raised $435.2M net in April 2026 public offering.
- SPY001 achieved 40% clinical remission and 51% endoscopic improvement; SPY002 achieved 33% and 42%, respectively, in Part A of SKYLINE UC trial.
- Enrollment completed for Phase 2 SKYWAY basket trial in RA, PsA, axSpA; RA data expected September 2026, PsA/axSpA data in Q4 2026.
- Recognized $40.0M gain on milestone from sale of priority review voucher related to legacy asset pegzilarginase.

## SEC filing metadata
- accession: 0001636282-26-000098
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2026-08-04T20:05:45+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/0001636282-26-000098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/syre-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-26-000098
- JSON: https://secwatch.observer/filing/0001636282-26-000098.json
- Plain text: https://secwatch.observer/filing/0001636282-26-000098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.